May 31 – June 01, Moscow hosted the Xth International Congress “Neurorehabilitation-2018”. The event was held with support of the Ministry of Healthcare of Russia, Russian Association of Rehabilitation & the National Stroke Association (NSA). Within the framework of the Congress, an exhibition event was also held, in which LLC “Vectorpharm”, the distributor of preparations of LLC “Scientific Production Company “PHARMASOFT” (LLC “SPC “PHARMASOFT”), took part.

The scientific program of the Congress was devoted to rehabilitation in vascular diseases, injuries and tumors of central nervous system. During the Congress, an annual session was held for managers and employees of regional vascular centers and primary vascular units, where basic principles of organization of rehabilitation activities in patients with cerebral stroke in settings of vascular units and peculiarities of training personnel for work in vascular units were examined, criteria for efficacy of rehabilitation were discussed and clinical protocols were approved.

Symposium “Peculiarities of Management & Rehabilitation of Patient with Comorbid Vascular Diseases” aroused great interest of the Сongress participants, the Chairman of Symposium was Doctor of Medical Sciences, Professor, Head of the Department of Neurology of the Faculty of Additional Professional Education (FAPE) of Russian National Research Medical University (RNRMU) named after N.I. Pirogov Fedin Anatoly Ivanovich. More than 170 specialists from all regions and cities of the Russian Federation and the Republic of Kazakhstan participated in the Symposium.

In the Symposium program, Tatyana Alexandrovna Voronina, Doctor of Medical Sciences, Professor, FEDERAL STATE BUDGETARY INSTITUTION (FSBI) RESEARCH INSTITUTE (RI) of Pharmacology named after V.V. Zakusov, presented ischemia and hypoxia as universal mechanisms of development of vascular pathology. The speaker focused in detail on reasons for high sensitivity of brain to ischemia and hypoxia and the stages of development of ischemic cascade, which are universal for all organs and tissues. Anatoly Ivanovich Fedin, in his report, focused on clinical aspects of managing patients after a stroke and principles of secondary prevention. Multimodal neuroprotection, as one of fundamental parts of pharmacotherapy, was presented at the example of the preparation of Mexidol^®, which has a wide range of effects, both at neuronal and vascular levels. Schepankevich Larisa Alexandrovna, Doctor of Medical Sciences, Main Scientist Researcher of the Federal Research Center for Fundamental & Translational Medicine “Clinic of RIECM (Research Institute of Experimental & Clinical Medicine)” (Novosibirsk) presented her own clinical experience in managing patients with cerebral infarction with underlying metabolic syndrome and diabetes mellitus. Larisa Alexandrovna noted the problem of polypragmasy as one of reasons for poor adherence of patients to therapy, which is often the cause of unsatisfactory results of therapy. Solution of this problem is prescription of preparations with a wide range of pharmacological and clinical effects in adequate dosages. A new dosage of Mexidol^® – Mexidol^® FORTE 250 meets all these requirements. Mexidol^® FORTE 250 is a double dosage of the active ingredient in one film-coated tablet for patients with combined pathology, who require an increased dosage; a single drug with active substance of ethylmethylhydroxypyridine succinate with a double dosage. Mexidol^® FORTE 250 – when a great victory is needed.

The speaker has noted the fact that this dosage is extremely demanded and expected by both patients and specialists, as it allows to reduce the number of tablets per dose and improve results of therapy by increasing patient’s adherence to (compliance with) medical prescriptions.

At the stand of LLC “Vectorpharm”, doctors could take a close look at informational materials on problem of neurorehabilitation in modern medicine, clinical efficacy data on Mexidol in rehabilitation of stroke patients, including results of randomized, double-blind, multicenter, placebo-controlled study of effectiveness and safety of Mexidol in long-term sequential therapy in patients with hemispheric ischemic stroke in acute and early rehabilitation periods (EPICA).